@article {Pilati:2012:0929-8673:3900,
title = "Cancer Resistance to Type II Topoisomerase Inhibitors",
journal = "Current Medicinal Chemistry",
parent_itemid = "infobike://ben/cmc",
publishercode ="ben",
year = "2012",
volume = "19",
number = "23",
publication date ="2012-08-01T00:00:00",
pages = "3900-3906",
itemtype = "ARTICLE",
issn = "0929-8673",
url = "https://www.ingentaconnect.com/content/ben/cmc/2012/00000019/00000023/art00006",
doi = "doi:10.2174/092986712802002473",
keyword = "chemotherapy, DNA repair, chemoresistance, Cancer, biology of TOPO2 inhibitors, Type II topoisomerases, ubiquitously expressed enzymes, drugs, genomic DNA, topoisomerase",
author = "Pilati, P. and Nitti, D. and Mocellin, S.",
abstract = "Type II topoisomerases (TOPO2) are ubiquitously expressed enzymes that overcome topological problems in genomic DNA, which can result from DNA replication, transcription and repair. The class of compounds targeting TOPO2 includes some of the most active chemotherapy agents currently
available for the treatment of patients with different cancer types. Therefore, understanding of the molecular mechanisms underlying resistance to these drugs is of pivotal importance to improve their efficacy and ultimately increase the life expectancy of cancer patients. The first aim of
this review is to summarize the molecular biology of TOPO2 inhibitors, which is the key to understand cancer resistance to them; the second part of this work is dedicated to overview and discuss the available evidence on the mechanisms of resistance to these drugs, with special attention to
the strategies that might be useful to circumvent this phenomenon on the clinical ground.",
}